ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

Leukemia. 2020 Oct;34(10):2798-2804. doi: 10.1038/s41375-020-0844-7. Epub 2020 May 4.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use
  • Biomarkers, Tumor*
  • Cell Transformation, Neoplastic / genetics*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Humans
  • Leukemia / drug therapy
  • Leukemia / genetics*
  • Leukemia / metabolism
  • Leukemia / pathology
  • Molecular Targeted Therapy
  • Mutation*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / genetics*
  • Receptor, ErbB-2 / metabolism
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers, Tumor
  • Protein Kinase Inhibitors
  • ERBB2 protein, human
  • Receptor, ErbB-2